Trevi Therapeutics to Report Q4 and Year End 2021 Financial Results and Provide a Corporate Update on March 17, 2022
Trevi Therapeutics, Inc. (Nasdaq: TRVI) announced a conference call on March 17, 2022, at 4:30 p.m. ET to review its Q4 and full year 2021 financial results. The company is focused on developing Haduvio (nalbuphine ER) for treating serious conditions. Currently, Trevi is conducting Phase 2b/3 trials for chronic pruritus linked to prurigo nodularis and a Phase 2 trial for chronic cough in idiopathic pulmonary fibrosis patients. Haduvio has been granted Fast Track designation by the FDA for its proposed use.
- Conducting Phase 2b/3 clinical trials for chronic pruritus and Phase 2 trials for chronic cough.
- Haduvio has received Fast Track designation by the FDA.
- None.
NEW HAVEN, Conn., March 9, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER). Today, Trevi announced that management will host a conference call and live audio webcast on Thursday, March 17, 2022, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the fourth quarter and full year ended December 31, 2021.
To participate in the live conference call by phone, please dial (888) 317 6003 (domestic) or (412) 317 6061 (international) and provide access code 9674297. A live audio webcast will be accessible from the 'Investors & News' section on the Company's website at www.trevitherapeutics.com. An archived replay of the webcast will also be available for 30 days on the Company's website following the event.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio to treat serious neurologically mediated conditions. Trevi is conducting a Phase 2b/3 clinical trial of Haduvio for the treatment of chronic pruritus associated with prurigo nodularis (PN) and a Phase 2 trial for chronic cough in patients with idiopathic pulmonary fibrosis (IPF). These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems.
Founded in 2011, Trevi Therapeutics is headquartered in New Haven, CT.
About Haduvio
Haduvio, an investigational therapy, is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed ĸ-opioid receptor agonist and µ-opioid receptor antagonist that has been approved and marketed as an injectable for pain indications for more than 20 years in the United States and Europe. The ĸ- and µ-opioid receptors are known to be critical mediators of itch, cough and certain movement disorders. Nalbuphine's mechanism of action may also mitigate the risk of abuse associated with µ-opioid agonists because it antagonizes, or blocks, µ-opioid receptors. Parenteral nalbuphine is not currently classified as a controlled substance by the DEA in the United States or by regulatory authorities in most of Europe. Trevi intends to propose Haduvio as the trade name for nalbuphine ER. Nalbuphine ER (Haduvio) is an investigational therapy that has been granted Fast Track designation by the FDA for the proposed indication of reduction of moderate to severe pruritus in patients with prurigo nodularis. Its safety and efficacy have not been evaluated by any regulatory authority.
Investor Contact
Katie McManus
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com
Media Contact
Rosalia Scampoli
914-815-1465
rscampoli@marketcompr.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-report-q4-and-year-end-2021-financial-results-and-provide-a-corporate-update-on-march-17-2022-301499500.html
SOURCE Trevi Therapeutics, Inc.
FAQ
When will Trevi Therapeutics report its Q4 and year-end 2021 financial results?
What is Haduvio and what is it being tested for?
What significance does the Fast Track designation have for Haduvio?
How can I access the conference call on March 17, 2022?
